What is the quality and efficacy of the Laos generic version of giritinib?

The emergence of the generic version of Gilteritinib in Laos has provided a more economical and feasible treatment option for many patients with FLT3 mutant acute myeloid leukemia (AML). Giritinib is a new oral FLT3 inhibitor, developed by Astellas, targeting FLT3-ITD And FLT3-TKD mutations exert targeted inhibitory effects and show significant efficacy in relapsed or refractory AML. Although the drug has been successfully launched in mainland China, the price is still high because it has not been included in medical insurance, and it is also difficult for domestic patients to purchase it in hospitals. Therefore, more and more patients are turning their attention to overseas generic drug markets, especially the Laotian version of giritinib, which is affordable and gradually recognized for its quality.

From the perspective of the drug itself, the original drug geritinib has been approved by the FDA in the United States, the EMA in Europe and the China Food and Drug Administration, and is widely used in international clinical trials. Its therapeutic advantage is reflected in its highly selective inhibition of FLT3 mutations and improved progression-free survival and overall survival of patients with relapsed AML. However, the prices of original drugs are extremely high, especially the Hong Kong version of gilitinib. The latest market price is as high as 100,000 yuan per box, which prohibits many low- and middle-income patients. In contrast, the generic version of giritinib produced in Laos only costs more than 1,000 to 2,000 yuan, significantly reducing the economic burden.

So, are the quality and efficacy of generic drugs in Laos reliable? This has become the most important issue for patients when choosing. In fact, Laos has gradually established a registration and supervision system for generic drugs in recent years. Well-known generic drug manufacturers such as Lucius (LuqMed) have relatively mature drug research and development and production capabilities. The Lao version of giritinib has the same pharmaceutical ingredients as the original drug, and is formulated in accordance with international standards. Some products have also been approved by the Lao Ministry of Health and have corresponding registration batch numbers. This means that from the perspective of pharmacological ingredients and theoretical mechanisms, Lao generic drugs have a therapeutic basis that is close to that of the original drugs.

In addition, according to feedback from some patients and informal data from third-party medical platforms, the Lao version of giritinib can effectively control the progression of leukemia in clinical use. Some patients have improved their blood conditions and significantly alleviated their symptoms after treatment. However, since generic drugs usually lack large-scale, systematic international clinical trial data support, their safety and long-term efficacy still require close monitoring and tracking by clinicians. But what is certain is that, as an alternative with significantly reduced costs, Lao gilitinib can be used as a transitional treatment in most cases, helping patients gain precious time and hope for survival.

It needs to be emphasized that although the Laotian generic giritinib performs well in terms of price and preliminary efficacy, patients still need to choose purchasing channels carefully. There are many counterfeit products or drugs circulated through unregulated channels in the generic drug market. If patients purchase them through informal platforms, there is a risk of insufficient efficacy or safety hazards. Therefore, it is recommended that patients obtain drugs through qualified overseas medical service platforms, cross-border medical institutions or certified pharmacies, and use them under the guidance of professional hematologists to avoid changing the dosage or frequency on their own.

In general, the Lao generic version of giritinib, with its affordable price and basically consistent drug ingredients, provides hope for AML patients with limited financial conditions but in urgent need of treatment. Although there are still gaps with original drugs in terms of authoritative clinical data, quality consistency evaluation, etc., in the context of continued intensification of global pressure on drug accessibility, this type of cost-effective drugs is becoming a viable option in reality. In the future, with the accumulation of more clinical observations and real-world research, the application scope of Laos' generic giritinib may be further expanded, bringing substantial therapeutic help to more patients.

Reference materials:https://www.xospata.com/